HGH Fragment 176-191 Peptide: Lipolysis Claims and Honest Evidence
HGH Fragment 176-191 peptide guide covering the C-terminal growth hormone fragment, lipolysis claims, animal versus weak human fat-loss evidence and safety.
HGH Fragment 176-191 is the peptide-market name for the fat-mobilizing tail end of human growth hormone. The marketing logic is the same one used for its better-known cousin: take the part of growth hormone that breaks down fat, leave behind the growth-promoting and insulin-disrupting machinery, and use that short fragment as a cleaner fat-loss tool.
That idea produced legitimate laboratory research decades ago. It has not, so far, produced convincing human fat-loss evidence. The most developed version of this fragment, AOD-9604, was carried into human obesity trials and failed to show enough weight loss to justify further development. The unmodified 176-191 fragment sold on the research market has even thinner human data than that.
This guide is educational and not medical advice. HGH Fragment 176-191 is not an FDA-approved treatment for weight loss, body composition or any other use, and research-market products carry identity, purity, sterility and legal risks that published animal studies do not address.
HGH Fragment 176-191 At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | The C-terminal fragment of human growth hormone, roughly residues 177 to 191 (the last 15 to 16 amino acids). |
| Main marketing claim | Fat loss through lipolysis without growth hormone's IGF-1 and blood-sugar effects. |
| Best preclinical evidence | Rodent studies showing reduced body-weight gain, lower fat mass and increased lipolysis. |
| Human fat-loss evidence | Essentially none for the unmodified fragment; the optimized analog AOD-9604 failed a 24-week trial. |
| Relationship to AOD-9604 | AOD-9604 is an engineered analog of this fragment (Tyr-hGH 177-191) and is the more-studied version. |
| Status | Research-only; not FDA approved; WADA-prohibited for athletes. |
What HGH Fragment 176-191 Actually Is
Human growth hormone is a 191-amino-acid protein. Researchers in the 1990s, led by F. M. Ng and colleagues at Monash University in Australia, reported that much of growth hormone's fat-mobilizing activity could be reproduced by a small domain at the carboxyl terminus of the molecule, spanning amino acid residues 177 to 191. That domain is the basis for everything sold today as "HGH Fragment 176-191," "HGH Frag 176-191" or "Frag 176-191."
The naming is loose. The natural sequence corresponds to roughly residues 177 to 191, but the research-peptide market almost universally labels it "176-191." More importantly, the unmodified fragment is not the same molecule as AOD-9604. AOD-9604 is an engineered analog: it adds a tyrosine to the N-terminal end, producing Tyr-hGH(177-191), a 16-amino-acid hexadecapeptide that was optimized for stability and oral activity. Most of the cleaner, better-documented lipolysis experiments were actually run on that modified analog (also called AOD9401 in early work), not on the plain fragment.
This distinction matters when reading product pages. Vendors freely blur HGH Fragment 176-191, AOD-9604, full recombinant growth hormone and growth-hormone secretagogues such as CJC-1295 and ipamorelin. Those are biologically different things. Full growth hormone is a regulated drug with broad endocrine effects. Secretagogues act upstream by changing how much growth hormone the pituitary releases. HGH Fragment 176-191 is a short peptide claimed to act peripherally on fat cells.
The Lipolysis Mechanism, As Claimed
The mechanistic story is genuinely interesting, which is part of why this fragment keeps resurfacing. In isolated rat adipose tissue, the synthetic 177-191 domain stimulated hormone-sensitive lipase and inhibited acetyl-CoA carboxylase, mimicking the way intact growth hormone shifts fat cells toward breaking down stored triglyceride and away from making new fat. In obese-mouse work, the fragment reduced body-weight gain, decreased adipose tissue mass and significantly inhibited lipogenesis.
A key claimed advantage is what the fragment does not do. In the rodent studies, the modified fragment did not compete for the growth hormone receptor and did not induce cell proliferation, unlike intact growth hormone. It also did not raise IGF-1 and, critically, did not induce the hyperglycemia or insulin-secretion suppression that chronic full-length growth hormone caused in the same models. Later work in obese mice and beta-3 adrenergic receptor knockout mice suggested beta-3 adrenergic receptor biology was relevant to the chronic weight and lipolysis effects.
Two cautions belong with that mechanism. First, lipolysis, meaning the mobilization of fatty acids from fat cells, is not the same as losing body weight. Mobilized fat that is not oxidized is simply re-esterified back into storage. Second, most of this favorable mechanistic detail comes from the optimized analog and from isolated tissue or rodent models, not from the unmodified fragment in humans.
What The Evidence Actually Shows
The honest reading of HGH Fragment 176-191 is that the animal evidence is real but the human evidence is weak to absent.
| Evidence layer | What it supports | What it does not support |
|---|---|---|
| Isolated adipose tissue | The 177-191 domain can stimulate hormone-sensitive lipase and inhibit lipogenesis. | Predictable fat loss in living humans. |
| Obese mouse studies | Synthetic hGH 177-191 reduced weight gain and adipose mass over chronic treatment. | A validated human dose, route or outcome. |
| Obese Zucker rat studies | Oral AOD-9604 cut body-weight gain by more than half without harming insulin sensitivity. | That the same effect occurs in humans at any marketed dose. |
| Human obesity program (AOD-9604) | A modest early signal at one dose. | Approvable efficacy; the 24-week trial in 536 subjects failed and development stopped in 2007. |
That last row is the most important fact in this article. The optimized, better-absorbed, more-developed version of this exact fragment was tested in humans and did not work well enough to continue. The plain 176-191 fragment that research vendors sell has no comparable controlled human fat-loss trial behind it at all. If the engineered analog could not clear the bar, there is no basis for assuming the parent fragment quietly does better.
For broader context on why peripheral "fat-burner" mechanisms rarely translate into meaningful weight loss, see peptides for weight loss.
Half-Life And Practical Limits
Pharmacokinetic data for the unmodified fragment is poorly characterized in the primary literature. For the AOD-9604 analog, detection and metabolism work reported a very short plasma half-life, on the order of a few minutes after intravenous dosing, with rapid sequential degradation from the N-terminal end. That short circulating life is part of why this class is awkward to study and why dosing claims on vendor pages are not grounded in validated human pharmacokinetics. For background on why this number matters, see the peptide half-life guide.
Safety And Status
| Safety or status issue | Why it matters |
|---|---|
| Not FDA approved | HGH Fragment 176-191 is not approved for weight loss or any indication, and the parent program for AOD-9604 was discontinued. |
| Limited human safety data | Short-term human data exists for AOD-9604; the unmodified fragment has little controlled human safety characterization. |
| Compounding concerns | FDA has flagged immunogenicity, peptide-impurity and characterization concerns for compounded AOD-9604, which informs the related fragment. |
| WADA-prohibited | Growth hormone fragments including hGH 176-191 and AOD-9604 are on the prohibited list. |
| Product-quality risk | Research-market vials are not verified for identity, sterility or purity, independent of any clinical paper. |
Because the fragment did not raise IGF-1 or disrupt glucose in animal models, it is sometimes marketed as side-effect-free. That overstates a small, short-term, mostly preclinical safety picture. Absence of evidence of harm in rodents is not the same as demonstrated long-term safety for injectable use in people. For the broader risk picture across this class, see growth hormone peptide side effects.
How It Compares
Versus AOD-9604: AOD-9604 is the engineered, more-studied descendant of this fragment. It was specifically modified for better stability and oral absorption and still failed in human obesity trials. The unmodified 176-191 fragment should be read as the less-developed parent, not as an upgrade.
Versus growth-hormone secretagogues: peptides such as CJC-1295, ipamorelin and GHRP-2 work by a completely different route. They push the pituitary to release more of the body's own growth hormone, which then raises IGF-1 and carries growth hormone's full systemic profile. HGH Fragment 176-191 is the opposite design idea: a peripheral fragment claimed to act on fat cells without that systemic axis. Neither approach has good controlled human fat-loss evidence, but they should not be discussed as interchangeable.
If the terminology here is unfamiliar, the primer on what peptides are explains how fragments, analogs and secretagogues differ.
Bottom Line
HGH Fragment 176-191 is a real molecule with a real preclinical story. The C-terminal lipolytic domain of growth hormone can stimulate fat breakdown in isolated tissue and reduce fat mass in obese rodents, apparently without growth hormone's effects on IGF-1 and blood sugar. That is the strongest honest claim that can be made.
The weakness is human translation. The optimized version of this fragment, AOD-9604, was the one carried into human obesity development, and it failed. The unmodified fragment sold today has even less human evidence, no validated dose, a very short half-life in its analog form, no FDA approval and WADA-prohibited status. The accurate summary is that HGH Fragment 176-191 is a research-stage lipolytic fragment with promising animal data and unconvincing human fat-loss evidence, not a proven weight-loss peptide.
References
Natera SH, Jiang WJ, Ng FM. Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide. Biochem Mol Biol Int. 1994.
Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000.
Ng FM, Jiang WJ, Gianello R, Pitt S, Roupas P. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. J Mol Endocrinol. 2000.
Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001.
Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001.
Cox HD, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015.
Habibullah MM, Mohan S, Syed NK, et al. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther. 2022.
World Anti-Doping Agency. The Prohibited List: growth hormone fragments including hGH 176-191 and AOD-9604.